Q-linea AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Q-linea AB's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:QLINEs's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.37 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Q-linea AB (CHIX:QLINEs) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Q-linea AB 5-Year Yield-on-Cost % Related Terms
CHIX:QLINES vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Q-linea AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Q-linea AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Q-linea AB is calculated as
Q-linea AB (CHIX:QLINES) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #999999 out of 327 companies in the Medical Devices & Instruments industry.
Is Q-linea AB's 5-Year Yield-on-Cost % too high?
Q-linea AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Q-linea AB ranks #999999 out of 327 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Q-linea AB has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #999999 out of 327 companies for 5-Year Yield-on-Cost %. This places Q-linea AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.37, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is kr1,921.76, compared to a current price of kr1,610.00 — trading 16.2% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Q-linea AB's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 16.2% below its estimated GF Value™ of kr1,921.76.
Key valuation signals for CHIX:QLINES:
5-Year Yield-on-Cost %: 0.00
GF Value™: kr1,921.76 vs. price of kr1,610.00 (16.2% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
67GF Score
Get the complete analysis for CHIX:QLINES
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 